We are live on ! Find out more
CGTX icon

Cognition Therapeutics

75 hedge funds and large institutions have $16.3M invested in Cognition Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.3% less ownership

Funds ownership: 24.27% → 23.97% (-0.3%)

4% less funds holding

Funds holding: 78 → 75 (-3)

21% less capital inflows, than outflows

Capital inflows: $1.25M | Capital outflows: $1.57M

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

Holders
75
Holders Change
-3
Holders Change %
-3.85%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
10
Increased
17
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CGTX Hedge Fund Activity: Q1 2026 in Review

75 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2026, worth a combined $16.3M — down 44% from $28.9M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CGTX and 10 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 17 added.

The largest buyer was CM Management, adding an estimated $233K. The largest seller was Jane Street, cutting an estimated $284K.

  • 75 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2026, down from 78 in Q4 2025.
  • Funds reported $16.3M of Cognition Therapeutics stock for Q1 2026, down 44% quarter-over-quarter.
  • 10 funds opened new Cognition Therapeutics positions in Q1 2026 and 14 closed out, a net change of -4 holders.
  • The largest Cognition Therapeutics buyer in Q1 2026 was CM Management, an estimated $233K added.
  • The largest Cognition Therapeutics seller in Q1 2026 was Jane Street, an estimated $284K sold.

Based on aggregated 13F filings for Q1 2026.